Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of
Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product.
Merck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Designation for Bavencio, this time in combination with Pfizer’s Inlyta
